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Abstract 32 
Antivenoms against bites and stings from snakes, spiders, and scorpions are associated 33 
with immunological side effects and high cost of production, since these therapies are still 34 
derived from the serum of hyper-immunized production animals. Biotechnological 35 
innovations within envenoming therapies are thus warranted, and phage display 36 
technology may be a promising avenue for bringing antivenoms into the modern era of 37 
biologics. Although phage display technology represents a robust and high-throughput 38 
approach for the discovery of antibody-based antitoxins, several pitfalls may present 39 
themselves when animal toxins are used as targets for phage display selection. Here, we 40 
report selected critical challenges from our own phage display experiments associated 41 
with biotinylation of antigens, clone picking, and the presence of amber codons within 42 
antibody fragment structures in some phage display libraries. These challenges may be 43 
detrimental to the outcome of phage display experiments, and we aim to help other 44 
researchers avoiding these pitfalls by presenting their solutions. 45 
  46 
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1. Introduction 47 
Envenomings from snakes, scorpions, and spiders represent a serious neglected health 48 
issue in large parts of the developing world, causing pain and suffering to millions of 49 
victims with severe cases resulting in amputation (for snakebite) or even death (David 50 
Warrell et al., 2007; Williams et al., 2011). The cornerstone of envenoming therapies still 51 
consist of animal-derived antisera, which remain the only effective treatment options 52 
against snakebites, spider bites, and scorpion stings (Chippaux, 2012; Everardo Remi 53 
Rodríguez Rodríguez et al., 2015; Gutiérrez et al., 2011). However, since antisera suffer 54 
from drawbacks including immunogenicity due to their heterologous nature, complex 55 
production processes due to dependence on venoms and the immune systems of production 56 
animals, and batch-to-batch variation, an increasing amount of research is being focused on 57 
alternative approaches based on monoclonal antibodies and recombinant DNA technology 58 
(Laustsen et al., 2016a, 2016c; Richard et al., 2013; Rodríguez-Rodríguez et al., 2016; 59 
Roncolato et al., 2015). These novel approaches may hold the promise of delivering 60 
biotechnology-based therapies with improved efficacy, higher safety, and potentially lower 61 
cost of production (Laustsen et al., 2016a, 2016b; Rodríguez-Rodríguez et al., 2016). 62 
One approach that has gained increasing attention within development of novel 63 
antivenoms is the use of phage display technology for discovery of antibodies and antibody 64 
fragments (Roncolato et al., 2015). Phage display technology exploits the linkage between 65 
antibody genotype and phenotype obtained by incorporating antibody genes, typically 66 
single-chain variable fragments (scFvs) or single-domain antibody fragments (VHHs or 67 
Nanobodies®) (Figure 1) into the DNA of bacteriophages displaying the antibody peptide 68 
sequence on its outer coat (Laustsen, 2016a) (Figure 2). In addition to phage display 69 
technology, several other approaches for development of novel antivenoms and antitoxins 70 
have been investigated, such as the use of small molecules (Lewin et al., 2016), the use of 71 
DNA epitopes strings (Harrison, 2004; Wagstaff et al., 2006), or the use of hybdridoma 72 
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technology (Castro et al., 2014; Frauches et al., 2013). However, it is beyond the scope of 73 
this article to discuss these approaches in detail (see (Laustsen et al., 2016a, 2016d; 74 
Roncolato et al., 2015) for comprehensive reviews of these topics).  75 
In phage display experiments, the M13 bacteriophage is often employed to create a 76 
library, where antibody fragments are displayed on the pIII coat protein of the M13 phage 77 
virion, while the antibody fragment encoding gene is incorporated into the DNA of the 78 
phage virion (Hoogenboom et al., 1998; Rodi and Makowski, 1999; Sidhu, 2000), see Figure 79 
2. The phage display library is then used for in vitro selection by attaching the target 80 
antigen to a plate well or bead, and panning the phage virions onto the target (Parmley and 81 
Smith, 1988). Non-binding phages are then washed away after sufficient incubation time, 82 
and binding phages can be eluted, amplified in E. coli TG1, and either subjected to 83 
additional rounds of panning or analysis (typically ELISA or gel electrophoresis). After a 84 
few cycles of panning, monoclonal phage virions can be isolated and their DNA sequenced 85 
in order to reveal the sequence of the displayed antibody fragment (Laustsen, 2016a). 86 
Several factors influence the outcome of a phage display experiment, including the 87 
introduction of deselection steps to remove unwanted antibody fragments, the affinity of 88 
the displayed antibody fragments, the level of antibody display, antigen immobilization and 89 
presentation, and clonal variation. Clonal variation may further affect antibody fragment 90 
translation, folding, transport, and stability of the fusion, which may further create 91 
amplification biases towards phage virions displaying undesired antibody fragments 92 
(Barbas et al., 1991; Bass et al., 1990; Garrard et al., 1991; John McCafferty, 1996; Lowman 93 
et al., 1991).  94 
Since McCafferty et al. reported the development of the first scFv phage display library 95 
in 1990 (McCafferty et al., 1990), a wealth of antibodies and antibody fragments have 96 
successfully reached the clinic for a wide range of indications (Nelson and Reichert, 2009; 97 
Schofield et al., 2007). In the field of antivenom development, phage display technology 98 
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was already introduced in 1995 when Meng et al. isolated the first murine scFv against 99 
different Mojave rattlesnake toxins (Meng et al., 1995). Since then, other researchers have 100 
reported the discovery of both human scFvs and camelid VHHs against phospholipases A2 101 
and neurotoxins from both vipers and elapids (Chavanayarn et al., 2012; Kulkeaw et al., 102 
2009; Richard et al., 2013; Roncolato et al., 2013; Stewart et al., 2007; Tamarozzi et al., 103 
2006). Yet, antivenoms have still not entered the modern era of biopharmaceuticals, where 104 
protein-based therapies are produced recombinantly (Laustsen, 2016a; Laustsen et al., 105 
2016a, 2016d). Part of the reason that this transition from serum-based therapies to 106 
recombinant antivenoms has not yet occurred is due to the difficulty of obtaining sufficient 107 
funding and resources for developing complex biologic therapies against conditions 108 
affecting mainly poor and rural communities of the tropical regions of the world. However, 109 
another part of the explanation could be the different technical obstacles encountered in 110 
phage display experiments, where animal venom toxins are used as targets. Many animal 111 
venom toxins are difficult to isolate in sufficient amounts and in high purity (Roncolato et 112 
al., 2015), the venoms may be difficult to procure, and the medically relevant venom 113 
components need to be identified (Laustsen et al., 2015c), which may be further 114 
complicated by toxin synergism (Laustsen, 2016b). In addition to some of the general 115 
considerations when using phage display technology, including loss of diversity during the 116 
panning and amplification rounds (Derda et al., 2011) and ineffective incorporation of the 117 
pIII-antibody protein (Roncolato et al., 2015), other specific challenges may be encountered 118 
in antitoxin discovery projects based on phage display. 119 
In this paper, we report five non-obvious obstacles that we have encountered in our 120 
research within antitoxin phage display. These obstacles have significantly delayed our own 121 
research, and therefore we wish to help other researchers by discussing how they present 122 
themselves and their solutions. It should be noted that the results presented here are from 123 
our ongoing work on developing toxin-neutralizing antibodies and antibody fragments. 124 
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Thus, our antibodies and antibody fragments are at the time of writing still undergoing 125 
preclinical evaluation. However, irrespectively of whether our efforts of developing 126 
toxin-neutralizing antibodies will be successful, the challenges and solutions presented here 127 
are universal in nature for the identification of toxin-binding and/or toxin-neutralizing 128 
antibody fragments. Although these obstacles and solutions presented here do not 129 
exhaustively cover all challenges that may be encountered in phage display experiments, it 130 
is the hope that they may help the growing number of researchers already engaged or about 131 
to engage in development of next generation antivenoms against snake, scorpion, spider, 132 
and bee envenomings. Additional tricks for optimizing phage display experiments exists. 133 
These include switching of saturant (blocking buffer) between panning rounds, the use of 134 
chaotrophic agents during pannings, or performing pannings at low or elevated temperature 135 
to select for binder with thermostability (or to preserve antigens that are unstable at given 136 
temperatures). Other phage display challenges, including avidity, clonal variation, stability 137 
of the antigen, and the level of display, are discussed elsewhere (John McCafferty, 1996). 138 
 139 
2. Materials and Methods 140 
2.1. Venoms and toxins 141 
Venom fractions containing Short neurotoxin 1, dendrotoxins, and α-elapitoxins from the 142 
venom of D. polylepis were purified according to the protocol given in (Laustsen et al., 143 
2015d). D. polylepis venom and purified α-cobratoxin from N. kaouthia were obtained from 144 
Latoxan SAS, France. A. laevis venom was obtained from four specimens kept at the 145 
National Aquarium, Den Blå Planet, Denmark, frozen, lyophilized, and kept at -20 °C. 146 
PLA2s were isolated according to a protocol similar to the one found in (Laustsen et al., 147 
2015b). All toxins employed in the studies reported here were in a molecular range of 6 148 
kDa to 14 kDa. 149 
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2.2. Biotinylation 150 
 Different toxins from Naja kaouthia and Dendroaspis polylepis were dissolved in 151 
phosphate buffered saline (PBS, Dulbecco’s Phosphate Buffered Saline Sigma-Aldrich) to 152 
yield concentration between 0.5 to 6 µg/µl. Biotin linked to N-hydroxysuccinimide (NHS) 153 
via two different linkers (Aliphatic linker: EZ-Link™ Sulfo-NHS-LC-Biotin, No-Weigh™ 154 
Format, 21327, Thermo Scientific. PEG4-linker: EZ-Link™ NHS-PEG4-Biotin, 155 
No-Weigh™ Format, 21329, Thermo Scientific) was added in toxin to biotinylation reagent 156 
at ratios from 1:1.5 to 1:20 according to the protocol supplied by the manufacturer and left 157 
at room temperature for 30 min. Purification of the biotinylated toxins was achieved using 158 
buffer exchange columns (Vivacon 500, Sartorius, 2000 Da Molecular Weight Cut-Off). 159 
After three washes with 500 µL PBS, the columns were turned and the biotinylated toxins 160 
were eluted in 100-200 µL PBS. 161 
The extent of biotinylation of the toxins was assessed using a Pierce™ Fluorescence 162 
Biotin Quantitation Kit (46610, Thermo Scientific), following the protocol supplied by the 163 
manufacturer. 164 
Protein concentrations were determined using absorbances measured on a BMG 165 
labtech PHERAStar Fluorescence Spectrophotometer and individually calculated extinction 166 
coefficients (http://web.expasy.org/protparam/). 167 
2.3. MS analysis 168 
Purified biotinylated toxins and native toxins were adsorbed onto C18 micro-ZipTips 169 
(Millipore) to wash out any salt contaminants, after which the toxins were eluted with 2 uL 170 
50% acetonitrile in water, containing 0.1% trifluoroacetic acid, directly onto an OptiTOF 171 
384 plate. Immediately following, the eluate was mixed with 0.6L matrix (saturated 172 
α-cyanohydroxycinnamic acid in 50% acetonitrile, 0.1% TFA) and allowed to dry. The 173 
samples were analyzed by MALDI-TOF in a Proteomics Analyzer 4800 Plus mass 174 
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spectrometer (Applied Biosystems) operated in positive linear mode. Spectra were acquired 175 
using 1000 shots at a laser intensity of 4800. 176 
2.4. Phage display selection protocol 1 (phospholipases A2 from Aipysurus laevis) 177 
 Three phage display selection rounds using Tomlinson I + J libraries were carried out 178 
as described in the following. MaxiSorp™ plates (NUNC, Roskilde, Denmark) were coated 179 
with 100 µl of phospholipases A2, A. laevis crude venom, or streptavidin (Sigma-Aldrich, 180 
Saint Louis, USA) dissolved in PBS at a concentration of 0.01 µg/µl and left overnight at 4 181 
°C. Uncoated wells were left with PBS. The following day, wells with directly coated toxin 182 
were washed three times with PBS, filled to the brim with 2% milk powder (Fluka 183 
analytical) dissolved in PBS (2% M-PBS), and incubated at room temperature for two 184 
hours in order to block the wells. Streptavidin-coated wells were blocked for one hour with 185 
2% M-PBS, after which 100 µl biotinylated toxin (1 µg) dissolved in 2% M-PBS was 186 
added and left for one hour to bind. After blocking and binding of biotinylated toxin, all 187 
wells were washed three times with PBS and approximately 1013 phages dissolved in 100 µl 188 
2% M-PBS of library I and J respectively were added and incubated for one hour at room 189 
temperature with shaking (250 rpm), followed by one hour of incubation at room 190 
temperature without shaking. Supernatant was discarded and the plates were washed ten 191 
times with PBS containing 0.1% Tween® 20 (PBST, Sigma-Aldrich). Phages were eluted 192 
by adding 100 µl per well of trypsin-PBS (diluted 1:5 in PBS, Sigma-Aldrich). Supernatant 193 
was transferred to an Eppendorf tube containing 600 µl of E. coli TG1 grown in 2xTY to an 194 
OD600 = 0.4 and was incubated at 37 °C for 30 minutes without shaking. The cells were 195 
then spun down at 11,600 x g for five minutes, resuspended in 50 µl 2xTY, and plated out 196 
on TYE-agar (containing 100 µg/ml ampicillin and 1% glucose). All plates were incubated 197 
(bottom up) overnight at 37 °C. 198 
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The following day, 2 ml 2xTY was added to the overnight grown plates and the cells 199 
were loosened with a spreader. From these solutions, 10 µl was transferred to 10 ml fresh 200 
2xTY containing 100 µg/ml ampicillin and 1% glucose and incubated until OD600 = 0.4 was 201 
reached (approx. 1 hour). Following this, 5 x 1010 helper phage in 100 µl was added to the 202 
10 ml and incubated at 37 °C without shaking for 30 minutes. The culture was spun down 203 
at 3,000 x g (Sigma Centrifuge 4K15) for ten minutes and the pellet resuspended in 25 ml 204 
of 2xTY containing 100 µg/ml ampicillin, 50 µg/ml kanamycin, and 0.1% glucose, and 205 
incubated overnight at 30 °C. The following day, the overnight culture was spun down at 206 
3,300 x g for 15 minutes. Then, 6.25 ml PEG/NaCl (20% Polyethylene glycol 6000, 2.5 M 207 
NaCl) was mixed well with supernatant and left on ice for one hour. This solution was then 208 
spun at 3,300 x g for 30 min, the PEG/NaCl was discarded, and the pellet resuspended in 2 209 
ml PBS. The resuspended pellet was spun at 11,600 x g for ten minutes (to remove cellular 210 
debris) and 1 ml of the phage containing supernatant was transferred to a new 1.5 ml 211 
microcentrifuge tube. Two more rounds of selection were performed according to the 212 
procedure described above. 213 
Isolation of monoclonal binders was achieved by plating out individual E. coli TG1 214 
colonies on TYE-agar plates. Colonies from these plates were transferred using an 215 
inoculation loop into 100 µl 2xTY containing 100 µg/ml ampicillin and 1% glucose in 96 216 
well plates and grown shaking overnight at 37 °C. The following day, 20 µl was transferred 217 
from the overnight plates to a second 96 well plate containing 200 µl of 2xTY with 100 218 
µg/ml ampicillin and 1% glucose. These were grown for one hour at 37 °C. Then 25 µl 219 
2xTY containing 100 µg/ml ampicillin, 1% glucose, and 109 helper phage was added to 220 
each well. The plate was incubated another hour at 37 °C, while shaking. Afterwards, the 221 
plate was centrifuged for ten min at 1,800 x g and the supernatant was aspirated off. The 222 
pellet was resuspended in 200 µl 2xTY containing 100 µg/ml ampicillin and 50 µg/ml 223 
kanamycin and grown overnight shaking at 30 °C. The following day, overnight cultures 224 
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were spun down at 1,800 x g for ten minutes and 50 µl of the supernatant was mixed with 225 
50 µl 4% M-PBS and used in monoclonal phage ELISA as described in section 2.6. 226 
2.5. Phage display selection protocol 2 (α-cobratoxin from Naja kaouthia) 227 
 Vials (NUNC, Immuno Tube MaxiSorp, PK3000) were coated with 250 µL 10 µg/mL 228 
streptavidin (Pierce® Streptavidin, 21125, Thermo Scientific) in PBS and left at 4 °C 229 
overnight. 100 mL of 2xYT media was inoculated with E. coli TG1 and incubated at 250 230 
rpm and 37 °C overnight. 231 
Next day, the vials were washed three times with 4 mL PBS and blocked with 4 mL 232 
3% milk in PBS (M-PBS) for 1 hour at room temperature. Meanwhile, 420 µL of IONTAS 233 
phage library (an updated version of the library developed by Schofield et al. (Schofield et 234 
al., 2007)) was mixed with 420 µL 6% M-PBS and 840 µL 3% M-PBS and incubated for 1 235 
hour at room temperature to pre-block the library. Simultaneously, 420 µL of Dynabeads 236 
M-280 Streptavidin (10 mg/mL, 11206D, Invitrogen by Life Technologies) was washed 237 
three times with 800 µL 3% M-PBS and re-suspended in 1 mL 3% M-PBS and incubated 238 
for 1 hour on a rotor. After one hour of blocking with M-PBS, 250 µL of 5 g/ml 239 
biotinylated toxin (Dp4, Dp5, Dp6, Dp7, Dp8, and Dp20 from D. polylepis and 240 
α-cobratoxin (and α-Cbtx) from Naja kaouthia) in 3% M-PBS was added to the vials. The 241 
vials were then incubated at room temperature for 1 hour. The Dynabeads M-280 242 
Streptavidin centrifuged at 15,000 rpm for 5 min, the supernatant removed, and the beads 243 
were re-dissolved in 420 µL 3% M-PBS. The beads were then mixed with the pre-blocked 244 
library and incubated for 1 hour at room temperature on a rotor. Meanwhile, an appropriate 245 
amount (determined by OD measurement) of the overnight TG1 culture was added to a 246 
shake flask containing 100 mL 2xYT and set to grow at 37 °C at 250 rpm for 1-2 hours. 247 
After 1 hour on rotor, the phage library was separated from the beads by 1 min 248 
centrifugation at 15,000 rpm (Eppendorf Centrifuge 5417R), followed by placing the 249 
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Eppendorf tube on a magnetic rack, and using a pipette. The vials were washed five times 250 
with PBS, and 250 µL of the separated phage solution was added to the vials, which were 251 
then incubated at room temperature for 1 hour. The vials containing the phages were 252 
washed six times with 4 mL PBS + 0.2% Tween® 20 and six times with 4 mL PBS. Then, 253 
250 µL of trypsin in Phage Elution Buffer (1/100 dilution of TPCK-trypsin from 10 µg/mL 254 
stock in 50 mM Tris pH 8, 1 mM CaCl2) was added to the vials, and the vials were 255 
incubated at room temperature for 15 min. The solutions from the vials were added to 256 
Falcon tubes containing 5 mL TG1 culture with an OD600 of 0.5, which were incubated at 257 
37 °C at 150 rpm for 1 hour. After incubation, 10 µL of the cultures were added to 258 
Eppendort tubes containing 990 µL 2xYT. After mixing, two 2xYT-AG (2xYT containing 259 
2% glucose and 100 µg/mL ampicillin) plates were prepared for each culture by adding 10 260 
µL of the solutions and 100 µL of the solutions, respectively to each plate. The plates were 261 
incubated at 30 °C overnight and counted next day to determine cfu. The remaining 262 
solutions in the Falcon tubes were centrifuged for 10 min at 2100 g (Heraus Megafuge 40R 263 
Centrifuge). The supernatants were discarded, and the pellets were re-suspended in 50 µL 264 
2xYT and plated out on an 2xYT-AG plate. The plates (termed Output plates) were 265 
incubated at 30 °C overnight. As controls, 200 µL of the TG1 culture was also plated out on 266 
both a 2xYT-AG plate and a 2xYT-KG plate (2xYT containing 2% glucose and 50 µg/mL 267 
kanamycin). The 2xYT-AG plate was incubated at 30 °C overnight. The 2xYT-KG plate 268 
was incubated at 37 °C overnight. 269 
Next day, the Output plates were scraped using 2 mL of a solution containing: 14 mL 270 
of 2xYT, 6 mL of 50% glycerol, and 100 µg/ml ampicillin. The 2 mL were transferred to 271 
50 mL Falcon tubes and rotated for 30 min. A sufficient amount (determined by OD600) of 272 
the Output scraping was used to inoculate 10 mL of 2xYT-AG to obtain an OD600 of 0.1. 273 
These new suspensions were incubated at 37 °C at 250 rpm for 1.5 hours. The remaining of 274 
the Output scrapings were stored in cryo tubes at -80 °C. Once the incubated solutions had 275 
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reached an OD600 of 0.4-0.5, 100 µL of MK13KO7-trp helper phages (1/3000 dilution of 6 276 
x 1014 phage/mL in 2xYT-AG) was added, and the solutions were incubated at 37 °C at 277 
150 rpm for 1 hour. After 1 hour, the cells were centrifuged for 10 min at 2100 g. The 278 
supernatants were removed by decanting. The cells were re-suspended in Erlenmeyer flasks 279 
containing 40 mL of 2xYT-AK (2xYT containing 100 µg/mL of Ampicillin and 50 µg/mL 280 
of Kanamycin) and incubated at 25 °C at 280 rpm overnight. 281 
Next day, the different solutions incubated in Erlenmeyer flasks were transferred to 282 
Falcon tubes and spun down at 10,500 g for 10 min (Sorvall Lynx 4000 Centrifuge). The 283 
supernatants were transferred to 50 mL Falcon tubes containing 10 mL 20% PEG-8000 + 284 
2.5 M NaCl, mixed, and kept on ice for 1 hour to allow precipitation. After 1 hour, the 285 
phages were centrifuged at 15,000 g for 10 min (Sorvall Lynx 4000 Centrifuge). The 286 
supernatants were discarded, and the phage pellets were re-suspended in 500 µL PBS in 287 
Eppendorf tubes. The Eppendorf tubes were centrifuged at 9,300 g for 10 min (Eppendorf 288 
Centrifuge 5417R), and the supernatants were transferred to other Eppendorf tubes to get 289 
rid of cell debris. This was done twice more, since cell debris continued to be present. 290 
Two more rounds of selection were performed according to the procedure described 291 
above with two exceptions: 1) In round 2 and 3, the phage libraries were not pre-incubated 292 
with Dynabeads M-280 Streptavidin. 2) Instead of streptavidin, 10 µg/mL NeutrAvidin 293 
(NeutrAvidin™ Biotin Binding Protein, 31000, Thermo Scientific) was used for coating in 294 
round 2 to deselect the streptavidin-binding phages. 295 
2.6. ELISA protocol 1 296 
 Polyclonal phage binders to the toxins, obtained from the Tomlinson I + J libraries 297 
after each of the rounds of selection, were investigated using ELISA. First, a MaxiSorp™ 298 
plate was coated with toxins or streptavidin overnight as described in section 2.5. The 299 
following day, wells coated with toxin were washed three times with PBS, filled to the brim 300 
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with 2% M-PBS, and incubated at room temperature for two hours to block the wells. 301 
Streptavidin-coated wells were blocked for one hour with 2% M-PBS, after which 100 µl 302 
biotinylated toxin (1 µg) dissolved in 2% M-PBS was added, and the well was left for one 303 
hour to allow biotin capture. Each well was then washed three times with PBST and two 304 
times with PBS to remove unspecific binders. Then, a mixture of 50 µl 4% M-PBS and 50 305 
µl phage from each panning round was added to their respective wells and incubated for 306 
one hour on a plate shaker. Wells were then washed three times with PBS and two times 307 
with PBST, and 100 µl of solution containing a 1:1000 dilution of anti-M13 monoclonal 308 
antibody (Horseradish Peroxidase conjugated, GE Healthcare) in 2% M-PBS was added to 309 
each well and incubated at one hour at room temperature on a plate shaker. Wells were 310 
washed three times with PBST and two times with PBS. Then 100 µl of OPD solution (2 311 
mg ortho-Phenylenediamine, DAKO, and 2.5 µL H2O2 in 2.5 ml H2O) was added to each 312 
well to achieve color development. Reactions were stopped by adding 100 µl 0.5 M H2SO4 313 
(Sigma-Aldrich) to each well and absorbances were measured at 490 nm (VersaMax 314 
Tunable Microplate reader, Molecular Devices). 315 
2.7. ELISA protocol 2 316 
The progress of the panning rounds in Phage Display Experiment 2 was monitored by 317 
ELISA. Each panning round was tested against the following antigens: Dp4, Dp5, Dp6, 318 
Dp7, Dp8, and α-cobratoxin, and synthesized epitopes (Epitope 1, 2, and 3) representing 319 
linear epitopes from type 1 and type 2 α-neurotoxins from D. polylepis (Laustsen, 2016a). 320 
Wells (NUNC, MaxiSorp) were coated with 100 µL 10 µg/mL streptavidin (Pierce® 321 
Streptavidin, 21125, Thermo Scientific) in PBS and left at 4 C overnight. Control wells 322 
were coated with 10 µg/mL NeutrAvidin (NeutrAvidin™ Biotin Binding Protein, 31000, 323 
Thermo Scientific). 324 
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Next day, the wells were washed three times with PBS and blocked with 200 µL 2% 325 
M-PBS for 1 hour at room temperature on a mixer. The wells were then washed three times 326 
with PBS. 50 µl of 1 µg/ml of all different antigens and 50 µL of 10 µg/ml for selected 327 
peptides (Epitope 1, Epitope 2, Epitope 3) in 2% M-PBS was added to their respective 328 
wells, and the plates were incubated for 2.5 hours at room temperature on a mixer. The first 329 
control wells (NeutrAvidin) were left in or 200 µL of 2% M-PBS, while the second control 330 
wells (streptavidin) wells were left in 50 µl of 2% M-PBS on a mixer. The wells were 331 
washed three times with PBS. Solutions of 50 µl of the different 50x phage libraries 332 
(dilution 1/100 in 2% M-PBS) found during selections rounds were added to their 333 
respective wells in duplicates. The wells were put on mixer for 1 hour. The wells were 334 
washed three times with PBS + 0.2% Tween® 20 and three times with PBS. 50 µL of 335 
Mouse anti-M13 antibody (GE Healthcare) in 2% M-PBS (dilution 1/1000) was added to 336 
each well. The wells were put on mixer for 1 hour, followed by three washes with PBS + 337 
0.2% Tween® 20 and three times with PBS. 100 µL of Europium labeled anti-mouse 338 
antibody (Perkin Elmers) in 2% M-PBS (dilution 1/1000) was added to each well. The 339 
wells were put on mixer for 1 hour, washed three times with PBS + 0.2% Tween® 20 and 340 
three times with PBS. 100 µL of DELFIA enhancement solution was added to each well. 341 
The wells were put on mixer for 5 minutes. The plates were read using a BMG labtech 342 
PHERAStar Fluorescence Spectrophotometer (excitation 340 nm, emission 615 nm). 343 
 344 
3. Results and discussion 345 
The pitfalls presented here were encountered during the course of approximately 346 
50 different phage display selection experiments against snake venom toxins involving 347 
different displayed peptide, VHH, and human scFv phage display libraries. From these, 348 
the results presented here will utilize six illustrative experiments with human scFv 349 
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libraries, of which four were run in parallel against phospholipases A2 from the olive 350 
sea snake, Aipysurus laevis, according to section 2.4 in Materials and Methods, and 351 
two were run in sequence against α-cobratoxin, the medically most important toxin 352 
from the monocled cobra, Naja kaouthia (Laustsen et al., 2015a), according to section 353 
2.5 in Materials and Methods.  354 
3.1. Optimal display of antigens via biotinylation 355 
Biotinylation of antigens involves the covalent attachment of a biotin molecule to the 356 
antigen via a chemical linker. Biotinylation may be employed for obtaining a better display 357 
of the antigen, as the linker will enable the antigen to be distanced from the solid-phase 358 
surface, when streptavidin coated wells, beads, or vials are used for panning, thereby 359 
avoiding conformational change of the antigen and reducing the possibility of steric 360 
hindrance in the antigen-antibody interaction. Although biotinylation may thus provide 361 
beneficial properties to a phage display selection experiment, this extra step may also bring 362 
about experimental complications, of which some will be discussed in the following. 363 
3.1.1. Biotinylation versus direct coating 364 
An important advantage of immobilization of biotinylated antigens to streptavidin via a 365 
linker in comparison with directly coated antigens is that the antigen may be better 366 
presented. This may allow for a larger part of its surface to interact with phage virions 367 
during pannings (Bronfman et al., 2003) and the achievement of better control of the 368 
concentration of bound antigen. Immobilization via a linker also allows the antigen to be 369 
distanced from the bottom and inner walls of the well, vial, or surface of a bead. This may 370 
contribute to better preservation of the native conformation of the antigen, which may in 371 
some cases be denatured when directly coated (see Figure 4A and 4B). However, the 372 
drawbacks of biotinylation include the addition of an extra (antigen consuming) step in the 373 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
 
discovery process and the possibility that biotinylation may interfere with a desired site on 374 
the antigen, which would have been optimal for selection.  375 
 In our experiments, we compared the outcomes from panning rounds with the 376 
Tomlinson I and J libraries (human scFv libraries) against both biotinylated PLA2s captured 377 
by streptavidin (see Figure 5A and 5B) and directly coated PLA2s from A. laevis (see 378 
Figure 5C and 5D). No normalization of the phage concentrations between different 379 
panning rounds was performed. Therefore the polyclonal ELISA results should mainly be 380 
used to evaluate signal ratios for a given panning round between target toxin and control. 381 
Based on the high signal intensities and signal ratios in ELISA assays between these 382 
different panning rounds, our results indicate that much better selection is obtained for the 383 
biotinylated PLA2s than for the un-biotinylated PLA2s, possibly due to better antigen 384 
presentation. Furthermore, when comparing the selectivity of polyclonal phage virions it is 385 
seen from the binding signals that phage virions from the Tomlinson I library selected 386 
against biotinylated PLA2s were specific towards the biotinylated PLA2s and did not bind 387 
to directly immobilized PLA2s after the third round of panning (Figure 6A). In contrast, 388 
phage virions from the Tomlinson J library selected against biotinylated PLA2s bind to both 389 
biotinylated PLA2s and native PLA2s (Figure 6B, panning round 3). The quality (e.g. 390 
diversity in displayed antibody fragments, naivety, and size) of a phage display antibody 391 
library is of high importance for the outcome of a phage display experiment. This is 392 
supported by the results presented in Figure 5 and Figure 6, from which it could be inferred 393 
that the Tomlinson Library I is of lower quality than the Tomlinson Library J in this given 394 
experiment, since selective PLA2 binders are more quickly accumulated from this library. 395 
Nevertheless, it is seen in Figure 6A that a large decrease in signal intensities in the ELISA 396 
occur for the Tomlinson Library I between the second and third round of panning, 397 
indicating that successful positive selection of selective binder against biotinylated PLA2 398 
has occurred. 399 
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Our results thus suggest that immobilization of PLA2s via biotinylation and 400 
streptavidin capture may provide better selection conditions for discovery of 401 
toxin-binding scFvs via phage display. As an alternative solution, other researchers 402 
have successfully employed amine binding plates for antigen immobilization via direct 403 
chemical coupling of toxins to the bottom of the wells (through a spacer) for the 404 
discovery of camelid VHH inhibitors of α-cobratoxin (Richard et al., 2013). Outside of 405 
toxinology, immobilization to streptavidin-coated beads has successfully been used to 406 
identify scFv binders via solution-based panning (see e.g. (Haque and Tonks, 2012)), 407 
however, since these approaches have not been employed to discover antitoxins, they 408 
will not be discussed further here, but may be worth exploring for the interested 409 
researcher. 410 
3.1.2. Over-biotinylation of antigen 411 
Although biotinylation of the antigen may provide better selection condition during a 412 
phage display experiment, it is of paramount importance that the antigen is optimally 413 
biotinylated (one biotin per antigen for small toxins). Over-biotinylation may lead to 414 
masking of the antigen itself, thereby hindering the phage virions from accessing it (Figure 415 
4C). In experiments performed with the IONTAS human scFv library (an updated version 416 
of the library developed by Schofield et al. (Schofield et al., 2007)) using α-cobratoxin as 417 
the antigen, two different batches of biotinylated α-cobratoxin were employed. In the first 418 
batch, α-cobratoxin had been biotinylated at a toxin-to-biotinylation reagent-ratio of 1:20 419 
(leading to over-biotinylation, see Figure 7). In the second batch, α-cobratoxin had been 420 
biotinylated at a toxin-to-biotinylation reagent-ratio of 1:1.5 (primarily leading to singly 421 
biotinylated antigen). The extent of biotinylation was originally assessed using the Pierce™ 422 
Fluorescence Biotin Quantitation Kit (46610, Thermo Scientific), according to which 423 
α-cobratoxin molecules had been biotinylated 0.7 times on average. However, when 424 
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assessed by MS (see Figure 7) it was evident that an average of 3-4 biotin moieties (each 425 
moiety having a mass of 0.5 kDa) had been conjugated to the antigen. This difficulty of 426 
over-biotinylation was unfortunately not immediately uncovered. Therefore, initial phage 427 
display selection experiments were performed, which did not yield polyclonal phage 428 
binders (Figure 8A). When the second batch of singly biotinylated α-cobratoxin was used, 429 
selection rounds yielded a good pool of α-cobratoxin binders that showed cross-recognition 430 
to homologous type 2 α-neurotoxins present in fractions Dp6 and Dp7 from D. polylepis 431 
venom (Figure 8B). 432 
Again, our results demonstrate the applicability of the biotinylation approach for 433 
snake toxins to be used as antigens in phage display selection experiments, but also 434 
underline the importance of obtaining an optimal biotin-to-toxin ratio. 435 
3.1.3. The effect of linker physico-chemistry 436 
 Many snake toxins have a small mass (three-finger toxins: 6-8 kDa and PLA2s: 12-14 437 
kDa), and since the biotinylation of a protein adds an additional 0.5 kDa to the molecule, 438 
the nature of the linker may have a profound effect on the physico-chemical properties of 439 
the antigen. Two different linkers were assessed in the biotinylation of different toxins 440 
(Aliphatic linker: EZ-Link™ Sulfo-NHS-LC-Biotin, No-Weigh™ Format, 21327, Thermo 441 
Scientific. PEG4-linker: EZ-Link™ NHS-PEG4-Biotin, No-Weigh™ Format, 21329, 442 
Thermo Scientific). In several experiments performed using the aliphatic linker, a white 443 
precipitate was clearly observed. In contrast, when using a hydrophilic PEG4-linker, no 444 
precipitate could be seen, and NanoDrop® measurements of protein concentration in the 445 
purified solutions of toxins biotinylated with the PEG4-linker confirmed that the 446 
biotinylated toxins were still in solution. It is therefore suggested that the hydrophobic 447 
nature of the aliphatic linker has a detrimental effect on the hydrophobicity of the 448 
biotinylated toxins leading to precipitation (Figure 9A). Thus, the use of more hydrophilic 449 
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linkers, such as the PEG4-linker, may indeed be favorable for small snake toxins, as it 450 
allows the toxins to remain in solution (Figure 9B).  451 
Additionally, the length of the linker may have an impact on antigen presentation, and 452 
it may occasionally be worthwhile to test different linker lengths to identify one that 453 
provides better display of the antigen. Taken together with the fact that streptavidin may 454 
bind up to four different biotin moieties, using biotinylation and streptavidin capture could 455 
at least theoretically lead to crowding of the presented toxins. This may potentially have 456 
negative effects on phage display selection experiments, as this may render entire or parts 457 
of the presented toxin antigen unavailable for binding interaction. 458 
 459 
3.2. Clone picking 460 
 In phage display selection experiments performed with the Tomlinson I and J libraries 461 
on biotinylated PLA2s from A. laevis, polyclonal ELISAs revealed that an accumulation of 462 
PLA2-specific phage virions had taken place in the course of the three panning rounds 463 
(Figure 5A and 5B). From the different panning rounds (particularly round 2 and 3) phage 464 
virions were used to transfect E. coli TG1 cells, which were plated out to yield monoclonal 465 
TG1 colonies. Two different screening experiments were then performed on selected 466 
colonies. In the first experiment 288 primarily large colonies were picked and screened by 467 
monoclonal ELISA. This yielded a low rate of positive PLA2-binders (3.8% of clones 468 
showing a signal three times higher than the background signal), see Figure 10A. Due to 469 
the somewhat unsuccessful outcome of this experiment, another 84 primarily small colonies 470 
were picked from the same plates and screened by monoclonal ELISA. In contrast, this 471 
yielded a high percentage of positive, selective PLA2-binders (54.8% of clones showing a 472 
signal three times higher than the background signal), see Figure 10B. This observation is 473 
likely to be explained by the fact that phage production may be proportional to colony size. 474 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
 
Phage virions with truncations in (or absence of) their displayed antibody fragment create 475 
less metabolic strain on their host cells. These host cells therefore have a growth advantage 476 
in comparison to cells infected by phage virions displaying fully functional high affinity 477 
scFvs (Bruin et al., 1999). Clones with a growth advantage multiply faster, allowing them 478 
to produce more phage virions, since more phage virion producing cells will be present and 479 
since each phage virion is produced with less metabolic cost. Therefore, such “non-antigen 480 
binding” phage virions will dominate the total pool of phage virions despite having a lower 481 
affinity to the antigen target (Umlauf et al., 2015). Also, antibody fragments that are toxic 482 
to bacteria may be deleted due to negative selection pressure during amplification 483 
(Schofield et al., 2007). Thus, supported by observations reported in the scientific literature, 484 
our results indicate that an undesired growth bias may interfere with isolation of high 485 
affinity toxin binders in phage display experiments. This growth bias may however to some 486 
extent be dealt with by careful selection of small colonies over larger ones. 487 
 488 
3.3. Amber codons in antibody libraries 489 
 A final pitfall that may be encountered when using certain libraries (such as the 490 
Tomlinson libraries) in phage display selection experiments is the presence of amber 491 
codons within the scFv fragment. Amber codons (TAG) are typically stop codons, which 492 
may however by some organisms and strains (such as the E. coli TG1 strain, which is a 493 
non-suppressor of the amber codon) be interpreted as a codon for glutamate. The amber 494 
codon is intentionally inserted after the myc-tag (see Figure 11) in e.g. the Tomlinson 495 
libraries, which allows for full biosynthesis of the scFv-pIII product in TG1 cells, but which 496 
will terminate protein synthesis in prior to gIII in non-suppressor strains (such as E. coli 497 
HB2151). This allows for easy expression of soluble scFvs following infection of a 498 
non-suppressor strain with phages directly after a phage display selection experiment. The 499 
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pitfall with amber codons, however, presents itself, when an amber codon is present within 500 
the scFv fragment – a phenomenon occurring due to the approaches used for construction 501 
of certain libraries (such as the Tomlinson library). When this occurs, the functional 502 
scFv-pIII product may be obtained from the TG1 strain and thus be enriched by phage 503 
display selection, but the construct will be prematurely terminated, when the soluble scFv 504 
expression is attempted in other strains. The presence of amber codons resulting in 505 
premature termination of protein synthesis has been reported by Wu et al. (Wu et al., 2007) 506 
and Roncolato et al. (Roncolato et al., 2015). In our phage display selection experiments 507 
against PLA2s from A. laevis, we encountered the amber codon in the CDR2 region of the 508 
VH of some of our scFv binders (Figure 11). In order to overcome this pitfall, it is a 509 
necessity to sequence the phagemid DNA and either introduce a glutamate encoding codon 510 
instead of the premature amber codon by site directed mutagenesis (Barderas et al., 2006), 511 
or simply to synthesize the entire scFv gene construct and transform it into the expression 512 
strain. This can be a cumbersome process, and undetected, it can lead to large amounts of 513 
wasted time. 514 
 515 
4. Concluding remarks 516 
The pitfalls presented here do not comprise an exhaustive set of challenges that may be 517 
encountered during phage display selection experiments with the purpose of identifying 518 
toxin-binding scFvs for the development of recombinant antivenoms. However, they do 519 
provide further insight into certain difficulties revolving around proper presentation of 520 
toxin antigens, how to avoid growth bias and select bacterial colonies expressing high 521 
affinity binder, and how to detect and possibly circumvent the difficulty that premature 522 
amber codons present in the scFv gene sequence represent. It is the hope that these findings 523 
may help to guide researchers in their efforts towards developing recombinant antivenoms 524 
against venoms from snakes, spider, scorpions, bees, and possibly other creatures, and that 525 
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such efforts may ultimately help envenomed victims in poor rural parts of the world, where 526 
most envenomings occur. 527 
 528 
  529 
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Figure legends 694 
 695 
Figure 1. Overview of the different antibody formats employed to construct phage 696 
display antibody libraries and how these formats relate to human (scFv) and camelid 697 
(VHH) antibodies, respectively. 698 
 699 
Figure 2. Schematic representation of the M13 bacteriophage containing 700 
single-stranded DNA (ssDNA) and displaying an scFv on the pIII protein. 701 
 702 
Figure 3. Schematic representation of a phage display selection experiment. (1) First 703 
the scFv displaying phage library is panned against the target toxin, which is bound to 704 
a well. (2) Non-binding phage particles are washed away. (3) Binding phage particles 705 
are eluted. (4) Phage particles are amplified and either submitted to another round of 706 
selection or (5) analyzed by polyclonal ELISA. 707 
 708 
Figure 4. Schematic representation of antigen coating strategies and problems during 709 
phage display selection. (A) When an antigen is coated directly onto the bottom of a 710 
well (or surface of a bead), the antigen may change its native conformation. (B) 711 
Biotinylation of the antigen may provide a way to distance the antigen from the 712 
solid-phase surface and into solution for better accessibility and to avoid 713 
conformational change of the antigen. (C) Over-biotinylation of antigens can lead to 714 
masking of the antigen epitopes, hampering their recognition by antibody paratopes. 715 
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Figure 5. Polyclonal ELISA results from Phage Display Experiment 1 with the 717 
Tomlinson Libraries I and J against PLA2s from A. laevis and control (uncoated) (see 718 
Materials and Methods 2.4). (A) Tomlinson Library I panned against biotinylated PLA2 719 
toxins. (B) Tomlinson Library J panned against biotinylated PLA2 toxins. (C) 720 
Tomlinson Library I panned against directly coated PLA2 toxins. (D) Tomlinson 721 
Library J panned against directly coated PLA2 toxins. 722 
 723 
Figure 6. Polyclonal ELISA results from Phage Display Experiment 1 with the 724 
Tomlinson Libraries I and J against biotinylated PLA2s and directly coated PLA2s from 725 
the A. laevis, streptavidin, and control (uncoated) (A) Tomlinson Library I. (B) 726 
Tomlinson Library J. 727 
 728 
Figure 7. MALDI-TOF mass spectra for α-cobratoxin from Naja kaouthia biotinylated 729 
with different toxin-to-biotinylation reagent-ratios showing that over-biotinylation 730 
(more than one biotin moiety per toxin molecule) occurs at higher 731 
toxin-to-biotinylation reagent-ratios. (A) Native α-cobratoxin. (B) Biotinylated 732 
α-cobratoxin, toxin-to-biotinylation reagent-ratio: 1:1. (C) Biotinylated α-cobratoxin, 733 
toxin-to-biotinylation reagent-ratio: 1:2. (D) Biotinylated α-cobratoxin, 734 
toxin-to-biotinylation reagent-ratio: 1:5 (over-biotinylation). (E) Biotinylated 735 
α-cobratoxin, toxin-to-biotinylation reagent-ratio: 1:10 (over-biotinylation). (F) 736 
Biotinylated α-cobratoxin, toxin-to-biotinylation reagent-ratio: 1:20 737 
(over-biotinylation). 738 
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Figure 8. Polyclonal phage ELISA for panning rounds 2 and 3 for the IONTAS scFv 740 
phage display library panned against α-cobratoxin from Naja kaouthia following Phage 741 
display selection protocol 2 (see Materials and Methods 2.5). (A) ELISA results from 742 
panning rounds using over-biotinylated α-cobratoxin (toxin-to-biotinylation 743 
reagent-ratio of 1:20). (B) ELISA results from panning rounds using α-cobratoxin with 744 
more optimal biotinylation (toxin-to-biotinylation reagent-ratio of 1:1.5). Dp5-Dp8: 745 
Fractions 5, 6, 7, and 8 from Dendroaspis polylepis containing Short neurotoxin 1, 746 
dendrotoxins, and α-elapitoxins (numbering according to (Laustsen et al., 2015d)). 747 
Cbtx: α-cobratoxin from N. kaouthia. 748 
 749 
Figure 9. Schematic representation of the effect of linker chemistry on the biotinylated 750 
antigen/toxin employed for phage display selection. ( ) The solubility of small toxins 751 
may be highly affected by aliphatic linkers, which can lead to precipitation of the 752 
biotinylated antigen, making it useless for coating. (B) Using hydrophilic linkers (such 753 
as PEG-linkers) may retain the solubility of the toxin, thereby providing better antigens 754 
for coating. 755 
 756 
Figure 10. Monoclonal ELISA results for clones selected from various panning rounds 757 
in Phage Display Experiment 1 (see Materials and Methods 2.4). (A) In the first 758 
attempt, 288 clones were picked from primarily large colonies, of which only a very 759 
low number displayed binding to PLA2. (B) In the second attempt, 84 clones were 760 
picked from small colonies, of which more than 50% displayed selective binding to 761 
PLA2. Note: Clones were ranked and numbered according to their signal intensities. 762 
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Figure 11. Conceptual sequence of one of our scFvs displaying the different elements 764 
of the scFv, the presence of a desired amber codon after the myc-tag, and an undesired 765 
amber codon in the CDR2 region of the VH. 766 
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Figure 9 791 
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Figure 11 797 
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